(Q42289001)

19 October 2017

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia (English)

1 reference

19 October 2017

1 reference

Estey E

1

1 reference

19 October 2017

Plunkett W

2

1 reference

19 October 2017

Gandhi V

3

1 reference

19 October 2017

Rios MB

4

1 reference

19 October 2017

Kantarjian H

5

1 reference

19 October 2017

Keating MJ

6

1 reference

19 October 2017

1 March 1993

1 reference

19 October 2017

1 reference

19 October 2017

9

1 reference

19 October 2017

4-5

1 reference

19 October 2017

343-350

1 reference

COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE.

19 October 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428199309148532

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199309148532

Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199309148532

Experience with Intermediate and High Dose Cytosine Arabinoside in Refractory Acute Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428199309148532

10.3109/10428199309148532

21 January 2018

Identifiers

DOI

1 reference

19 October 2017

1 reference